|
CN104274449A
|
|
Pharmaceutical composition for treating obesity
|
|
CN104274482A
|
|
Medicine for treating asthma
|
|
CN104274446A
|
|
Pharmaceutical composition for treating type 2 diabetes
|
|
CN104274452A
|
|
Application of composition in preparation of medicine for treating obesity
|
|
CN104274458A
|
|
Medicine for treating diabetes
|
|
CN104274447A
|
|
Pharmaceutical composition for treating fatty liver
|
|
CN104274450A
|
|
Pharmaceutical composition for treating liver insulin resistance
|
|
CN104274461A
|
|
Application of composition in preparation of medicine for treating atherosclerosis
|
|
CN104274457A
|
|
Application of composition in preparation of medicine for treating diabetes
|
|
CN104274443A
|
|
Pharmaceutical composition for treating diabetes
|
|
CN104274463A
|
|
Medicine for treating atherosclerosis
|
|
CN104274481A
|
|
Medicament for treatment of hepatic carcinoma
|
|
CN104274478A
|
|
Application of SGLT2 inhibitor in preparation of medicine for treating diabetes mellitus II
|
|
CN104274445A
|
|
Application of composition in preparation of medicine for treating type 2 diabetes
|
|
CN104274459A
|
|
Application of composition in preparation of medicine for treating diabetes
|
|
CN104274477A
|
|
SGLT2 inhibitor
|
|
CN104274448A
|
|
Application of composition in preparation of medicine for treating liver insulin resistance
|
|
CN104274451A
|
|
Application of composition in preparation of medicine for treating fatty liver
|
|
CN104274460A
|
|
Medicine for treating obesity-related diseases
|
|
CN104274462A
|
|
Application of composition in preparation of medicine for treating obesity-related diseases
|
